Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting
Go back to Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.75 -0.37 (11.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.12 | 52 Week High | $9.58 | |||
| Open | $2.66 | 52 Week Low | $2.34 | |||
| Day High | $2.85 | P/E | N/A | |||
| Day Low | $2.53 | EPS | $-0.34 | |||
| Volume | 11,199,247 | |||||
